<DOC>
	<DOCNO>NCT00354276</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , VNP40101M cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving VNP40101M follow cytarabine may kill cancer cell . PURPOSE : This phase II trial study well VNP40101M follow cytarabine work treat old patient acute myeloid leukemia .</brief_summary>
	<brief_title>VNP40101M Followed Cytarabine Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response rate old patient poor-risk , de novo acute myeloid leukemia treat VNP40101M induction therapy follow cytarabine consolidation therapy . Secondary - Determine probability overall survival , leukemia-free survival , progression-free survival patient treat regimen . - Determine safety regimen patient . OUTLINE : This open-label , multicenter study . - Induction therapy : Patients receive VNP40101M IV 60 minute day 1 ( course 1 ) . Patients without evidence disease progression respond residual disease receive second course VNP40101M day 35-60 . Patients achieve complete response partial response induction therapy proceed consolidation therapy . - Consolidation therapy : Beginning day 45-90 , patient receive cytarabine IV continuously 5 day ( course 1 ) . Patients may receive second course cytarabine discretion investigator . After completion study treatment , patient follow periodically 36 month . PROJECTED ACCRUAL : A total 85 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm de novo acute myeloid leukemia ( AML ) No acute promyelocytic leukemia [ ( 15 ; 17 ) ] No favorable cytogenetics , include ( 15 ; 17 ) , ( 8 ; 21 ) , inv 16 No secondary AML , define history antecedent hematologic disorder ( myelodysplastic syndrome [ MDS ] myeloproliferative disease ) , history prior chemotherapy radiation disease AML Must ≥ 1 follow poorrisk feature : Any follow unfavorable cytogenetics : Del ( 5q ) /5q 7/del ( 7q ) Abnormal 3q , 9q , 11q , 20q , 21q , 17p ( 6 ; 9 ) ( 9 ; 22 ) Trisomy 8 Complex karyotype ( ≥ 3 unrelated abnormality ) At least 70 year age ECOG performance status ( PS ) 2 Cardiac dysfunction* would limit use anthracycline therapy , define follow : Ejection fraction ≤ 50 % History significant coronary artery disease , define ≥ 1 vessel stenosis require medical treatment , stent placement , surgical bypass graft History congestive heart failure myocardial infarction Significant arrhythmia , include follow : Atrial flutter ( exclude atrial fibrillation ) Sick sinus syndrome Ventricular arrhythmia Heart valve disease Mitral valve prolapse allow Other heart disease , discretion principal investigator Pulmonary dysfunction relate AML , define 1 following : DLCO and/or FEV_1 &lt; 80 % ≥ 50 % normal range Dyspnea slight activity rest Requires oxygen Hepatic dysfunction relate chronic hepatitis liver cirrhosis Other organ dysfunction comorbidity preclude standard cytotoxic induction treatment ( e.g. , `` 3+7 '' ) , discretion principal investigator NOTE : *Patients history heart disease define must appropriate medication disease control No know CNS disease PATIENT CHARACTERISTICS : ECOG PS 02 AST ALT ≤ 5 time upper limit normal Bilirubin ≤ 2.0 mg/dL Creatinine ≤ 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment No active , uncontrolled infection Patients infection active treatment antibiotic whose infection control eligible Chronic hepatitis allow No clinical evidence ongoing second malignancy unrelated AML MDS No evidence leave bundle branch block screen ECG No obligate use cardiac pacemaker atrial fibrillation PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 24 hour since prior metronidazole No prior lowdose , singleagent , cytotoxic chemotherapy ( e.g. , cytarabine , decitabine , azacitidine ) No concurrent disulfiram No concurrent standard investigational therapy AML except follow : Concurrent hydroxyurea control rise white blood cell count Dosage must 46 gram daily 4 day Concurrent leukapheresis control blast cell count Must complete within first 5 day study therapy No 2 procedure per day 4 procedure total Investigational supportive care agent ( e.g. , antimicrobial antifungal agent ) , discretion protocol sponsor</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>